CLC bio releases groundbreaking whole-genome de novo assembler Today.

The task of hybrid assemblies: No other de novo assembly package can combine datasets from different sequencing technology.. CLC bio releases groundbreaking whole-genome de novo assembler Today, CLC bio released a groundbreaking whole-genome de novo assembler which will assemble genomes of any size, including human and plant genomes on a single workstation computer. Director of Scientific Software program Advancement at CLC bio, Dr. By empowering scientists around the global globe with this technology, the real number and size of de novo assembly projects increase. In accordance with our cross-platform strategy, we will support all of the upcoming Third Generation Sequencing technologies also, so our clients can reap the entire benefits of all of the exciting technological improvements of the future.LibiGel is in advancement for the treating feminine sexual dysfunction , particularly, hypoactive libido disorder in menopausal ladies, for which there is absolutely no FDA-approved product. ‘That is a significant milestone for BioSante. This accomplishment represents an integral positive stage toward completing the LibiGel Stage III clinical development system. To date, we’ve a combined enrollment inside our three LibiGel Stage III clinical research of around 4,000 ladies and we anticipate announcing completion of enrollment in the next efficacy trial soon,’ stated Joanne Zborowski, BioSante’s vice president of scientific development.

Anti-cancer antibodies produced in chickens A team of researchers have produced the 1st functional fully, individual sequence monoclonal antibodies in hens.